12-Nov-2024
Zai Lab Reports Strong Q3 Growth and Pipeline Progress
TipRanks (Tue, 12-Nov 11:12 PM ET)
Zai Lab GAAP EPADS of -$0.42 beats by $0.36, revenue of $102.27M in-line
Seeking Alpha News (Tue, 12-Nov 6:36 AM ET)
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Business Wire (Tue, 12-Nov 6:30 AM ET)
Here's the major earnings before the open tomorrow
Seeking Alpha News (Mon, 11-Nov 6:00 PM ET)
Zai Lab Q3 2024 Earnings Preview
Seeking Alpha News (Mon, 11-Nov 1:34 PM ET)
Zai Lab gets expanded Chinese approval for Vyvgart Hytrulo
Seeking Alpha News (Mon, 11-Nov 10:45 AM ET)
Business Wire (Mon, 11-Nov 7:30 AM ET)
Globe Newswire (Mon, 11-Nov 7:30 AM ET)
Business Wire (Tue, 29-Oct 7:30 AM ET)
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Zai Lab Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol ZLAB.
As of November 12, 2024, ZLAB stock price declined to $28.96 with 1,034,519 million shares trading.
ZLAB has a beta of 0.80, meaning it tends to be less sensitive to market movements. ZLAB has a correlation of 0.03 to the broad based SPY ETF.
ZLAB has a market cap of $2.88 billion. This is considered a Mid Cap stock.
Last quarter Zai Lab Limited - American Depositary Shares reported $101 million in Revenue and -$.82 earnings per share. This beat revenue expectation by $8 million and missed earnings estimates by -$.12.
In the last 3 years, ZLAB traded as high as $91.84 and as low as $13.48.
The top ETF exchange traded funds that ZLAB belongs to (by Net Assets): IBB, SBIO, PGJ, FMED, ONEQ.
ZLAB has underperformed the market in the last year with a price return of +2.8% while the SPY ETF gained +37.1%. However, in the short term, ZLAB had mixed performance relative to the market. It has outperformed in the last 3 months, returning +78.1% vs +12.3% return in SPY. But in the last 2 weeks, ZLAB shares have been beat by the market, returning -11.0% compared to an SPY return of +2.8%.
ZLAB support price is $30.00 and resistance is $32.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ZLAB shares will trade within this expected range on the day.